NASDAQ:EVAX Evaxion A/S (EVAX) Stock Price, News & Analysis $3.04 -0.03 (-0.85%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Evaxion A/S Stock (NASDAQ:EVAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Evaxion A/S alerts:Sign Up Key Stats Today's Range$3.01▼$3.2350-Day Range$2.79▼$3.4052-Week Range$2.77▼$12.15Volume24,728 shsAverage Volume91,352 shsMarket Capitalization$27.46 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingModerate Buy Company Overview Evaxion A/S is a Denmark-based biotechnology company developing artificial intelligence-driven immunotherapies. The company’s technology is designed to identify disease-specific targets, known as antigens, and support the development of personalized treatments that stimulate a patient’s immune system to recognize and attack diseased cells or pathogens. Evaxion’s research programs have focused primarily on personalized cancer immunotherapies, including EVX-01, as well as vaccines and immunotherapies for infectious diseases caused by bacteria and viruses. Its AI-Immunology platform is intended to analyze biological data, predict relevant immune targets and help design candidate therapies more efficiently than conventional discovery methods. Founded in Denmark, Evaxion has conducted research and development activities through collaborations with biotechnology and pharmaceutical organizations and has pursued clinical development of its cancer programs. The company’s American depositary shares began trading on the Nasdaq Capital Market in 2021. Evaxion is headquartered in Copenhagen, Denmark, and has been led by Chief Executive Officer Per Norlén.AI Generated. May Contain Errors. Read More Evaxion A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreEVAX MarketRank™: Evaxion A/S scored higher than 59% of companies evaluated by MarketBeat, and ranked 409th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingEvaxion A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEvaxion A/S has a consensus price target of $11.00, representing about 258.3% upside from its current price of $3.07.Amount of Analyst CoverageEvaxion A/S has only been the subject of 1 research reports in the past 90 days.Read more about Evaxion A/S's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Evaxion A/S is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evaxion A/S is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvaxion A/S has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Evaxion A/S's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.96% of the float of Evaxion A/S has been sold short.Short Interest Ratio / Days to CoverEvaxion A/S has a short interest ratio ("days to cover") of 1.21, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evaxion A/S has recently decreased by 5.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvaxion A/S does not currently pay a dividend.Dividend GrowthEvaxion A/S does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.89 News SentimentEvaxion A/S has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Evaxion A/S this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for EVAX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Evaxion A/S to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evaxion A/S insiders have not sold or bought any company stock.Percentage Held by Insiders41.64% of the stock of Evaxion A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions11.04% of the stock of Evaxion A/S is held by institutions.Read more about Evaxion A/S's insider trading history. Receive EVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evaxion A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVAX Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Elutia (ELUT) and Evaxion Biotech (EVAX)October 6, 2026 | theglobeandmail.comEvaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual MeetingOctober 2, 2026 | globenewswire.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.October 12 at 1:00 AM | Profits Run (Ad)Kurs Evaxion A/SSeptember 29, 2026 | de.marketscreener.comDKurs Evaxion A/SSeptember 29, 2026 | de.marketscreener.comDEvaxion applies its AI-Immunology™ platform in autoimmune diseasesSeptember 14, 2026 | globenewswire.comMerck (MRK) Takes An AI Vaccine Stake And Expands Its Discovery PlaybookAugust 23, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Boston Scientific (BSX)August 22, 2026 | theglobeandmail.comSee More Headlines EVAX Stock Analysis - Frequently Asked Questions How have EVAX shares performed this year? Evaxion A/S's stock was trading at $4.77 at the beginning of 2026. Since then, EVAX stock has decreased by 35.6% and is now trading at $3.07. How were Evaxion A/S's earnings last quarter? Evaxion A/S - Sponsored ADR (NASDAQ:EVAX) issued its earnings results on Thursday, May, 7th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.43. Read the conference call transcript. When did Evaxion A/S's stock split? Evaxion A/S shares reverse split on the morning of Monday, January 13th 2025.The 1-5 reverse split was announced on Monday, December 30th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. When did Evaxion A/S IPO? Evaxion A/S (EVAX) raised $31 million in an IPO on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager. How do I buy shares of Evaxion A/S? Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evaxion A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evaxion A/S investors own include PayPal (PYPL), Arista Networks (ANET), Tesla (TSLA), ChargePoint (CHPT), MercadoLibre (MELI), ASML (ASML). Company Calendar Last Earnings5/07/2026Today10/12/2026Study update10/29/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (9m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 EVAX's financial health is in the Yellow zone, according to TradeSmith. EVAX has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:EVAX CIK1828253 Webwww.evaxion.ai Phone45-5353-1850FaxN/AEmployees46Year Founded2008Price Target and Rating Average Price Target for Evaxion A/S$11.00 High Price Target$16.00 Low Price Target$9.00 Potential Upside/Downside+259.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.71 million Net MarginsN/A Pretax Margin-128.07% Return on Equity-61.43% Return on Assets-34.23% Debt Debt-to-Equity Ratio0.69 Current Ratio5.06 Quick Ratio5.06 Sales & Book Value Annual Sales$7.53 million Price / Sales3.66 Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book1.50Miscellaneous Outstanding Shares9,020,000Free Float5,265,000Market Cap$27.58 million OptionableNo Data Beta0.50 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:EVAX) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersTrump To Relaunch USD?President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredFree Ticker: Anthropic's silent partner could soar after record $2 trillion IPOAnthropic's IPO prospectus just leaked, revealing 261 pages tied to a record $2 trillion valuation. Beyond ...Monument Traders Alliance | SponsoredUrgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20thMarc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...Chaikin Analytics | SponsoredGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion A/S - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVAX Stock Alerts